Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elasomeran + imelasomeran
- Development stage
- Phase 4
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**mRNA-1273.214** is Moderna's bivalent COVID-19 mRNA vaccine marketed as **Spikevax Bivalent Original/Omicron BA.1**. It contains two nucleoside-modified mRNA active ingredients, elasomeran and imelasomeran, formulated in lipid nanoparticles. Elasomeran encodes the prefusion-stabilized spike protein of ancestral SARS-CoV-2, while imelasomeran encodes the Omicron BA.1 spike protein. Following intramuscular administration, host cells transiently express these antigens, eliciting neutralizing-antibody and cellular immune responses intended to prevent COVID-19 caused by SARS-CoV-2. The vaccine was developed and manufactured by Moderna and was authorized in multiple jurisdictions, including Canada and the European Union, for primary-series and booster use in eligible populations.
- Brand names
- Spikevax Bivalent Original/Omicron BA.1
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on elasomeran + imelasomeran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elasomeran + imelasomeran.